Product Licensing
Inovio Biomedical grants Wyeth license to develop infectious disease DNA vaccines
Published in Gene Therapy Weekly, December 7th, 2006
Under the terms of the agreement, Inovio will receive from Wyeth a $4.5 million upfront license fee, annual license maintenance fees, research support, and up to $60 million in payments based on successful completion of clinical and regulatory milestones. Inovio would exclusively supply Wyeth with electroporation devices for the vaccines...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-12-07)
More Articles from Gene Therapy Weekly
- Pancreatic Cancer
Rexin-G, first tumor-targeted gene therapy vector, stymies chemo-resistant cancer - Cancer Gene Therapy
Researchers from College of Medicine, Department of Microbiology discuss findings in cancer gene therapy - Cancer Gene Therapy
Researchers from Second Military Medical University, Department of Gastroenterology describe findings in cancer gene therapy - Chronic Lymphocytic Leukemia
Research from Moores Cancer Center provide new insights into chronic lymphocytic leukemia - DNA Vaccines
New DNA vaccines study findings recently were published by researchers at Peking Union Medical College, Medical College - DNA Vaccines
Studies in the area of DNA vaccines reported from Institute of Medical Education and Research, Department of Biochemistry - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
